Pilatus Biosciences Announces Hong Kong Clinical Trial Application Approval for PLT012 and Expansion into Hong Kong

Pilatus Biosciences, Inc., announced that the Hong Kong Department of Health has granted the Certificate for Clinical Trial / Medicinal Test for lead investigational therapy, PLT012 in patients with advanced solid tumors.